The field of regenerative medicine is approaching the goal of using stem cell therapy to replace part of an organ that has been damaged irreversibly. Our laboratory differentiates kidney organoids, 3D multicellular structures that functionally and compositionally resemble the respective organ they model, from human iPSCs (induced pluripotent stem cells). However, organoids we work with are largely avascular, whilst organs in vivo are highly vascularized. Our goal for this project is to build a microfluidic, vascular platform in which organoids can grow. To accomplish this, we adopted a microfluidic chip which was fabricated using soft lithography. Consequently, PDMS (polydimethylsiloxane), a polymer commonly used in soft lithography, was molded and bound to a glass coverslip using plasma binding. With this platform, we successfully engineered microvascular networks through vasculogenesis and angiogenesis and optimized the protocol of vascularization to sustain the cells by submerging the microfluidic chip in cell culture medium. Human umbilical vein endothelial cells and human lung fibroblasts were suspended in fibrinogen ECM (extracellular matrix), seeded into the microfluidic chips with micropillars to contain the cells within their respective channels, and developed into 3D microvascular networks with visible lumen. We then stained the vasculature with endothelial cell markers (i.e. CD31, CD54, VWF) and tested the perfusability by flowing polysterene beads through the microfluidic chip, observing the retention of polysterene beads within the vessels. Finally, we altered our design, specifically the height and width of the channels, to incorporate kidney organoids. Currently, we are using this platform for vascularizing kidney organoids and simultaneously implementing a flow system to induce shear stress on the microvasculature to attain physiological parameters. Ultimately, we aim to vascularize a kidney organoid to demonstrate the vascularization of stem cell tissue in vitro and see growth of tissue within our system, which would further our process in the translation pathway from bench to bedside for kidney regenerative medicine.